Peter Lawson

Stock Analyst at Barclays

(1.24)

# 3,369

Out of 4,778 analysts

97

Total ratings

35.06%

Success rate

-14.64%

Average return

Main Sectors:

Top Industries:

Biotechnology Diagnostics & Research

Stocks Rated by Peter Lawson

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	TCRX TScan Therapeutics	Maintains: Overweight	$14 → $3	$1.45	+107.61%	2	Mar 7, 2025
	GERN Geron	Maintains: Overweight	$9 → $4	$1.71	+134.60%	1	Feb 27, 2025
	EXEL Exelixis	Maintains: Equal-Weight	$25 → $29	$37.71	-23.10%	5	Feb 13, 2025
	ARVN Arvinas	Maintains: Overweight	$48 → $32	$8.13	+293.60%	7	Feb 3, 2025
	BMEA Biomea Fusion	Maintains: Equal-Weight	$9 → $11	$2.69	+308.92%	4	Oct 30, 2024
	RCUS Arcus Biosciences	Maintains: Overweight	$25 → $29	$8.40	+245.24%	6	Oct 25, 2024
	RVMD Revolution Medicines	Maintains: Overweight	$54 → $60	$38.46	+56.01%	3	Sep 27, 2024
	RLAY Relay Therapeutics	Maintains: Overweight	$14 → $17	$2.97	+473.36%	5	Sep 10, 2024
	SNDX Syndax Pharmaceuticals	Maintains: Overweight	$32 → $33	$13.46	+145.26%	4	Aug 15, 2024
	IMCR Immunocore Holdings	Maintains: Overweight	$92 → $66	$29.32	+125.10%	2	Aug 9, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$9 → $8	$1.80	+344.44%	8	Jul 31, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$75 → $105	$93.08	+12.81%	10	Jul 29, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$20 → $31	$12.59	+146.23%	2	Jul 15, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$13 → $17	$10.71	+58.73%	3	Jun 7, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$18 → $13	$1.64	+692.68%	1	May 24, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$18 → $22	$3.50	+528.57%	5	Feb 29, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$47 → $63	$47.25	+33.33%	3	Feb 29, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$6 → $10	$0.90	+1,007.30%	3	Feb 27, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Underweight	$2 → $1	$0.25	+296.98%	2	Aug 10, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$7 → $5	$0.70	+619.01%	4	Aug 4, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$210 → $120	$5.64	+2,027.66%	2	Aug 5, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Overweight	$30	$8.84	+239.37%	1	Jul 28, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$7 → $3.5	$0.62	+469.11%	4	Jul 7, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Underweight	$355 → $365	$87.50	+317.14%	1	Aug 6, 2021
	XXXX XXXXXXXXXXXXXXXX Upgrade	Upgrades: Overweight	$46	$30.76	+49.54%	2	Oct 22, 2020
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Underweight	$28	$11.82	+136.89%	1	Mar 4, 2020
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Overweight	$30	$0.83	+3,510.11%	1	Mar 4, 2020
	XXXX XXXXXXXXXXXXXXXX Upgrade	Upgrades: Buy	$17 → $45	$1.30	+3,361.54%	2	Jan 23, 2018
	XXXX XXXXXXXXXXXXXXXX Upgrade	Upgrades: Buy	$16 → $45	$40.88	+10.08%	2	Jan 23, 2018
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Buy	$70	$0.88	+7,836.51%	1	Jul 14, 2017

TScan Therapeutics

Mar 7, 2025

Maintains: Overweight

Price Target: $14 → $3

Current: $1.45

Upside: +107.61%

Geron

Feb 27, 2025

Maintains: Overweight

Price Target: $9 → $4

Current: $1.71

Upside: +134.60%

Exelixis

Feb 13, 2025

Maintains: Equal-Weight

Price Target: $25 → $29

Current: $37.71

Upside: -23.10%

Arvinas

Feb 3, 2025

Maintains: Overweight

Price Target: $48 → $32

Current: $8.13

Upside: +293.60%

Biomea Fusion

Oct 30, 2024

Maintains: Equal-Weight

Price Target: $9 → $11

Current: $2.69

Upside: +308.92%

Arcus Biosciences

Oct 25, 2024

Maintains: Overweight

Price Target: $25 → $29

Current: $8.40

Upside: +245.24%

Revolution Medicines

Sep 27, 2024

Maintains: Overweight

Price Target: $54 → $60

Current: $38.46

Upside: +56.01%

Relay Therapeutics

Sep 10, 2024

Maintains: Overweight

Price Target: $14 → $17

Current: $2.97

Upside: +473.36%

Syndax Pharmaceuticals

Aug 15, 2024

Maintains: Overweight

Price Target: $32 → $33

Current: $13.46

Upside: +145.26%

Immunocore Holdings

Aug 9, 2024

Maintains: Overweight

Price Target: $92 → $66

Current: $29.32

Upside: +125.10%

Jul 31, 2024

Maintains: Overweight

Price Target: $9 → $8

Current: $1.80

Upside: +344.44%

Jul 29, 2024

Maintains: Equal-Weight

Price Target: $75 → $105

Current: $93.08

Upside: +12.81%

Jul 15, 2024

Maintains: Overweight

Price Target: $20 → $31

Current: $12.59

Upside: +146.23%

Jun 7, 2024

Maintains: Overweight

Price Target: $13 → $17

Current: $10.71

Upside: +58.73%

May 24, 2024

Maintains: Overweight

Price Target: $18 → $13

Current: $1.64

Upside: +692.68%

Feb 29, 2024

Maintains: Overweight

Price Target: $18 → $22

Current: $3.50

Upside: +528.57%

Feb 29, 2024

Maintains: Overweight

Price Target: $47 → $63

Current: $47.25

Upside: +33.33%

Feb 27, 2024

Maintains: Overweight

Price Target: $6 → $10

Current: $0.90

Upside: +1,007.30%

Aug 10, 2023

Maintains: Underweight

Price Target: $2 → $1

Current: $0.25

Upside: +296.98%

Aug 4, 2023

Maintains: Equal-Weight

Price Target: $7 → $5

Current: $0.70

Upside: +619.01%

Aug 5, 2022

Maintains: Overweight

Price Target: $210 → $120

Current: $5.64

Upside: +2,027.66%

Jul 28, 2022

Initiates: Overweight

Price Target: $30

Current: $8.84

Upside: +239.37%

Jul 7, 2022

Maintains: Overweight

Price Target: $7 → $3.5

Current: $0.62

Upside: +469.11%

Aug 6, 2021

Maintains: Underweight

Price Target: $355 → $365

Current: $87.50

Upside: +317.14%

Oct 22, 2020

Upgrades: Overweight

Price Target: $46

Current: $30.76

Upside: +49.54%

Mar 4, 2020

Initiates: Underweight

Price Target: $28

Current: $11.82

Upside: +136.89%

Mar 4, 2020

Initiates: Overweight

Price Target: $30

Current: $0.83

Upside: +3,510.11%

Jan 23, 2018

Upgrades: Buy

Price Target: $17 → $45

Current: $1.30

Upside: +3,361.54%

Jan 23, 2018

Upgrades: Buy

Price Target: $16 → $45

Current: $40.88

Upside: +10.08%

Jul 14, 2017

Initiates: Buy

Price Target: $70

Current: $0.88

Upside: +7,836.51%